Madrigal Pharmaceuticals
MD, USA
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical...